Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- LDP Lawmakers Urge Expanded Fertility Treatment Support via Coverage, Subsidies
May 28, 2021
- Japan Approves Rinvoq for Psoriasis, More Drugs for Label Expansions
May 28, 2021
- MHLW Panels to Analyze Group-Based Data for Post-COVID-19 Vaccination Deaths
May 27, 2021
- Japan Panel Clears 1st Oral SMA Drug, 2 Migraine Meds, RNAi Therapy and More
May 27, 2021
- Next Drug Distribution Confab Set for July 2 after Bid-Rigging Verdicts
May 27, 2021
- Trintellix Braced for Price Cut as Chuikyo OKs CEA Results, Coralan Intact
May 27, 2021
- Chuikyo to Discuss Evaluation Rule for SaMD toward Next Reimbursement Reform
May 27, 2021
- Govt Mulls New AMED Organ to Lead Strategic Funding for Vaccine Development
May 26, 2021
- LDP Economic Growth HQ Hammers Out Proposal for Honebuto Paper
May 26, 2021
- Moderna Vaccine Likely to Be Used for Workplace Vaccination
May 26, 2021
- Japan Eyes Pfizer Vaccine Use in Younger People, Longer Refrigerator Storage
May 26, 2021
- 2nd Humira Biosimilar, 1st NovoRapid Follow-On Gets Japan Listing on May 26
May 25, 2021
- MHLW Panel Backs Japan’s 1st Oncolytic Virus for Conditional Approval
May 25, 2021
- MHLW Grants Orphan Status to Eculizumab, 2 More APIs
May 25, 2021
- Japan Hails Janssen Vaccine Submission as New Option: Spokesman
May 25, 2021
- MOF Panel’s Proposal Urges More Stringent Drug Cost Control, Revisiting of Semi-Automatic Listing
May 24, 2021
- Biz Improvement Order Issued to 3 Codevelopers over Kobayashi Kako’s Fudged Data
May 24, 2021
- LDP Project Team Submits Proposal to Boost Drug Discovery Capabilities
May 24, 2021
- PMDA Review Report: Flexible Discussions Needed for Eligibility of AstraZeneca Vaccine
May 24, 2021
- PMDA Reviewing New Safety Risk for Keytruda
May 24, 2021
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…